相关实验视频

Updated: Jul 4, 2025

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

在HFrEF的左心室重塑上Astragalus membranaceus的影响:系统性审查和元分析

Xu Han¹, Ting Yu², Xi Chen¹

¹Chongqing Changshou Traditional Chinese Medicine Hospital, Chongqing, China.

Frontiers in pharmacology

|January 29, 2024

概括

阿斯特拉加勒斯膜改善了心力衰竭患者的左心室重塑 (LVR) 减少喷射率 (HFrEF) 患者. 这种组合疗法增强了LVEF,并减少了心脏损伤标志物,而不会增加不良事件.

科学领域:

心脏病学心脏病学
综合医学是一个整体的医学.
药理学药理学是指药理学的学科.

背景情况:

左心室重塑 (LVR) 是心力衰竭与减少喷射率 (HFrEF) 的进展的一个关键因素.
有效的LVR管理对于延迟HFrEF进展和改善患者生活质量至关重要.
阿斯特拉加勒斯膜 (Astragalus membranaceus) 正在研究其对心血管疾病的潜在治疗作用.

研究的目的:

为了评估阿斯特拉加卢斯膜在改善左心室重塑 (LVR) 的疗效,在诊断为HFrEF的患者.
评估A. membranaceus与常规治疗 (CT) 结合对关键心脏和炎症标志物的影响.

主要方法:

随机对照试验 (RCT) 的系统审查和元分析,涉及HFrEF治疗的A. membranaceus.
搜索了8个中英数据库,截至2023年10月31日.
使用Cochrane手册偏差风险工具评估文献质量;使用Review Manager 5.4.1和Stata 17.0进行的元分析进行了敏感性和偏差分析.

主要成果:

有1565名患者的19个RCT显示,A. membranaceus与CT相结合显著改善左心室喷射率 (LVEF),并减少左心室末端透缩直径 (LVEDD) 和左心室末端透缩直径 (LVESD).
组合疗法改善了临床疗效,增加了6分钟的步行距离 (6-MWD),并降低了脑内尿素 (BNP) 水平.
与单独CT相比,A. membranaceus通过降低TNF-α,IL-6和hs-CRP来减轻炎症反应,但并没有显著增加不良反应.

结论:

与传统治疗相结合的Astragalus membranaceus组合疗法在改善HFrEF患者的LVR和临床结果方面比单独CT具有显著的优势.
治疗策略表现出良好的安全性,但并没有显著增加不良事件.
需要进一步进行高质量的临床研究,以巩固A. membranaceus在HFrEF管理中的常规临床应用的证据基础.

关键词:

阿斯特拉加勒斯的膜状.心力衰竭与减少的喷射分数心力衰竭左心室重塑的左心室重塑这是一个元分析.随机对照试验是随机对照试验.系统性审查系统性审查

更多相关视频

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...